Anti-Interferon-Inducible Protein 16 Antibodies Associate with Digital Gangrene in Patients with Scleroderma

Arthritis and Rheumatology

Volumn 68, Issue 5, 2016, Pages 1262-1271

  McMahan, Zsuzsanna H ^a   Shah, Ami A ^a   Vaidya, Dhananjay ^a   Wigley, Fredrick M ^a   Rosen, Antony ^a   Casciola Rosen, Livia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; INTERFERON INDUCIBLE PROTEIN 16 ANTIBODY; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE 1 ANTIBODY; UNCLASSIFIED DRUG; IFI16 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS SCLERODERMA; DIGITAL GANGRENE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GANGRENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK FACTOR; SCLERODERMA; SMOKING; AGED; FINGER; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGERS; GANGRENE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84964621958     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39558     Document Type: Article

References (25)

1. Wigley FM., Clinical practice: Raynaud's phenomenon. N Engl J Med 2002; 347: 1001-8.
2. Gabrielli A, Avvedimento EV, Krieg T., Scleroderma. N Engl J Med 2009; 360: 1989-2003.
3. Steen V, Denton CP, Pope JE, Matucci-Cerinic M., Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii19-24.
4. Veeranki S, Choubey D., Interferon-inducible p200-family protein IFI-16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization. Mol Immunol 2012; 49: 567-71.
5. Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo P, D'Ambrosio R, et al., A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI-16. Arthritis Rheum 2006; 54: 3939-44.
6. Costa S, Mondini M, Caneparo V, Afeltra A, Airo P, Bellisai F, et al., Detection of anti-IFI-16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology (Oxford) 2011; 50: 674-81.
7. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ., Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 688-93.
8. Steen V, Medsger TA Jr., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
9. Gariglio M, Azzimonti B, Pagano M, Palestro G, De Andrea M, Valente G, et al., Immunohistochemical expression analysis of the human interferon-inducible gene IFI-16, a member of the HIN200 family, not restricted to hematopoietic cells. J Interferon Cytokine Res 2002; 22: 815-21.
10. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
11. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
12. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
13. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al., A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
14. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al., Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
15. Morrone SR, Wang T, Constantoulakis LM, Hooy RM, Delannoy MJ, Sohn J., Cooperative assembly of IFI-16 filaments on dsDNA provides insights into host defense strategy. Proc Natl Acad Sci U S A 2014; 111: E62-71.
16. Steen VD, Medsger TA Jr., The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
17. Herrick AL, Heaney M, Hollis S, Jayson MI., Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis 1994; 53: 540-2.
18. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ., Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 688-93.
19. Wei W, Clarke CJ, Somers GR, Cresswell KS, Loveland KA, Trapani JA, et al., Expression of IFI 16 in epithelial cells and lymphoid tissues. Histochem Cell Biol 2003; 119: 45-54.
20. Gugliesi F, Mondini M, Ravera R, Robotti A, de Andrea M, Gribaudo G, et al., Up-regulation of the interferon-inducible IFI-16 gene by oxidative stress triggers p53 transcriptional activity in endothelial cells. J Leukoc Biol 2005; 77: 820-9.
21. Deng SX, Hanson E, Sanz I., In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies. Int Immunol 2000; 12: 415-23.
22. Douglas J, Gardner L, Levin M., Antibodies to an intracellular antigen penetrate neuronal cells and cause deleterious effects. J Clin Cell Immunol 2013; 4: 134.
23. Nihtyanova SI, Brough GM, Black CM, Denton CP., Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 67: 120-3.
24. Silva I, Almeida J, Vasconcelos C., A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev 2015; 14: 140-52.
25. Tramposch HD, Smith CD, Senecal JL, Rothfield N., A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984; 27: 121-4.